Author details

Full Name

Christos Hatzis

Affiliation

ORCID

Career Start Year

1990

Papers

136

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36797347	AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers.	NPJ Precis Oncol	2023
37841335	Evaluation of zero counts to better understand the discrepancies between bulk and single-cell RNA-Seq platforms.	Comput Struct Biotechnol J	2023
36650408	Assessment of stained direct cytology smears of breast cancer for whole transcriptome and targeted messenger RNA sequencing.		2023
35247885	Comprehensive Analysis of Metabolic Isozyme Targets in Cancer.	Cancer Research	2022
34374711	Intra- and Interlaboratory Reproducibility of the Sensitivity to Endocrine Therapy Assay for Stage II/III Breast Cancer.	Clin Chem	2021
33541297	Targeted RNAseq assay incorporating unique molecular identifiers for improved quantification of gene expression signatures and transcribed mutation fraction in fixed tumor samples.	BMC Cancer	2021
33902690	Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers.	Genome Med	2021
34211306	Diffuse Alveolar Hemorrhage after Receiving Oral Levonorgerstrel for Emergency Contraception: A Case Report.	Clinical Medicine Insights: Case Reports	2021
34040000	Treatment scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations.	npj Breast Cancer	2021
34634476	Data augmentation based on waterfall plots to increase value of response data generated by small single arm Phase II trials.	Contemporary Clinical Trials	2021
32840699	Increasing accrual of minority patients in breast cancer clinical trials.	Breast Cancer Research and Treatment	2020
32415133	Germline variant burden in cancer genes correlates with age at diagnosis and somatic mutation burden.	Nat Commun	2020
31919134	Analysis of Pre- and Posttreatment Tissues from the SWOG S0800 Trial Reveals an Effect of Neoadjuvant Chemotherapy on the Breast Cancer Genome.	Clinical Cancer Research	2020
32747940	Treatment efficacy for pharyngeal Neisseria gonorrhoeae: a systematic review and meta-analysis of randomized controlled trials.	Journal of Antimicrobial Chemotherapy	2020
32911681	Multi-Omics Investigation of Innate Navitoclax Resistance in Triple-Negative Breast Cancer Cells.	Cancers (Basel)	2020
30725384	Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women.	Breast Cancer Research and Treatment	2019
31624295	Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer.	Scientific Reports	2019
32914041	Genomic and Immune Profiling of a Patient With Triple-Negative Breast Cancer That Progressed During Neoadjuvant Chemotherapy Plus PD-L1 Blockade.	JCO Precis Oncol	2019
30139836	Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.	Oncologist	2019
30182250	Breast cancer patients with brain metastasis undergoing GKRS.		2019
30624555	Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.	Ann Oncol	2019
31025271	The impact of communication style on patient satisfaction.	Breast Cancer Research and Treatment	2019
31020471	Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy.	Breast Cancer Research and Treatment	2019
30967156	Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial.	J Immunother Cancer	2019
29588392	Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial.	Mol Cancer Ther	2018
30404001	Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic Heterogeneity.	Cell Rep	2018
30157950	Increased epigenetic age in normal breast tissue from luminal breast cancer patients.	Clin Epigenetics	2018
30203045	Immunological differences between primary and metastatic breast cancer.	Ann Oncol	2018
29902299	Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial.	JAMA Oncol	2018
30652574	TQuest, A Web-Based Platform to Enable Precision Medicine by Linking a Tumor's Genetic Defects to Therapeutic Options.	JCO clinical cancer informatics	2018
29396664	Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer.	Breast Cancer Research and Treatment	2018
29559730	An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes.	Br J Cancer	2018
29701764	Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.	Ann Oncol	2018
29372234	Comparison of Residual Risk-Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies.	JAMA Oncol	2018
29417299	First international TNBC conference meeting report.	Breast Cancer Res Treat	2018
28177460	Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.	Ann Oncol	2017
28428277	Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer.	Cancer Research	2017
28766195	Association of LN Evaluation with Survival in Women Aged 70 Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast Cancer.	Annals of Surgical Oncology	2017
28633466	Is complete response the answer?	Annals of Oncology	2017
28750120	Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer.	JAMA Oncology	2017
29048991	Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making.	Journal of Oncology Practice	2017
29177190	Functional germline variants as potential co-oncogenes.	npj Breast Cancer	2017
28236033	Co-targeting the HER and IGF/insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease.	Breast Cancer Research and Treatment	2017
27601588	Intratumor Heterogeneity of Homologous Recombination Deficiency in Primary Breast Cancer.	Clinical Cancer Research	2017
28135148	Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.	J Clin Oncol	2017
27872098	Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer.	Cancer Research	2017
27669414	Testing violations of the exponential assumption in cancer clinical trials with survival endpoints.	Biometrics	2017
28292938	Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor.	Mol Cancer Ther	2017
27959926	Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis.	PLoS Med	2016
27298406	T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab.	Journal of Clinical Oncology	2016